Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in
glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and …

Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …

Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase
inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the …

1558 Background: Erlotinib (Tarceva, OSI-774) is an orally available small molecule
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. We have initiated the first …

The purpose of this study was to define the maximum tolerated dose of erlotinib and
characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and …

2005 Background: In 40–50% of GBM epidermal growth factor receptor (EGFR) is amplified,
and often constitutively activated (EGFRvIII mutant). EGFR is therefore a potential …

1502 Purpose: To evaluate the efficacy of OSI-774, a small molecule tyrosine kinase
inhibitor of the epidermal growth factor receptor (EGFR), in patients with recurrent malignant …

The objective of this phase I study was to determine the maximal tolerated dose (MTD) of
erlotinib in patients with recurrent malignant gliomas (MGs) or recurrent meningiomas on …

Background Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic
target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma …